Report Thumbnail
Product Code LP09140104728XP
Published Date 2023/2/15
English120 PagesGlobal

Global Bacteriophage Therapy Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP09140104728XP◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/15
English 120 PagesGlobal

Global Bacteriophage Therapy Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.
LPI (LP Information)' newest research report, the “Bacteriophage Therapy Industry Forecast” looks at past sales and reviews total world Bacteriophage Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Bacteriophage Therapy sales for 2023 through 2029. With Bacteriophage Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bacteriophage Therapy industry.
This Insight Report provides a comprehensive analysis of the global Bacteriophage Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bacteriophage Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bacteriophage Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bacteriophage Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bacteriophage Therapy.
The global Bacteriophage Therapy market size is projected to grow from US$ 31 million in 2022 to US$ 61 million in 2029; it is expected to grow at a CAGR of 10.0% from 2023 to 2029.
The major players in global Phage Therapy market include NPO Microgen, Proteon Pharmaceuticals, Phagelux, etc. The top 3 players occupy about 25% shares of the global market. North America and Europe are main markets, they occupy about 60% of the global market. DsDNA Bacteriophage is the main type, with a share over 90%. Animal Health is the main application, which holds a share about 55%.
This report presents a comprehensive overview, market shares, and growth opportunities of Bacteriophage Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Topical
Parenteral
Segmentation by application
Organ Transplantation
Bacterial Infections
Alcoholic Hepatitis
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Armata Pharmaceuticals, Inc.
Eliava Biopreparations Ltd.
Pherecydes Pharma
Intralytix, Inc.
Phagelux Inc.
Nextbiotics
InnoPhage, Ltd
Locus Biosciences, Inc.
TechnoPhage
Eligo Bioscience SA
Phagomed Biopharma GmbH.
PhagePro, Inc.
Adaptive Phage Therapeutics, Inc.
EnBiotix, Inc.
Intodeworld, Inc.
BiomX Ltd.
Phi Therapeutics
Fixed-phage Ltd.
Micreos BV
ContraFect Corporation

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Bacteriophage Therapy Market Size 2018-2029
      • 2.1.2 Bacteriophage Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
    • 2.2 Bacteriophage Therapy Segment by Type
      • 2.2.1 Oral
      • 2.2.2 Topical
      • 2.2.3 Parenteral
    • 2.3 Bacteriophage Therapy Market Size by Type
      • 2.3.1 Bacteriophage Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
      • 2.3.2 Global Bacteriophage Therapy Market Size Market Share by Type (2018-2023)
    • 2.4 Bacteriophage Therapy Segment by Application
      • 2.4.1 Organ Transplantation
      • 2.4.2 Bacterial Infections
      • 2.4.3 Alcoholic Hepatitis
      • 2.4.4 Other
    • 2.5 Bacteriophage Therapy Market Size by Application
      • 2.5.1 Bacteriophage Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
      • 2.5.2 Global Bacteriophage Therapy Market Size Market Share by Application (2018-2023)
  • 3 Bacteriophage Therapy Market Size by Player

    • 3.1 Bacteriophage Therapy Market Size Market Share by Players
      • 3.1.1 Global Bacteriophage Therapy Revenue by Players (2018-2023)
      • 3.1.2 Global Bacteriophage Therapy Revenue Market Share by Players (2018-2023)
    • 3.2 Global Bacteriophage Therapy Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Bacteriophage Therapy by Regions

    • 4.1 Bacteriophage Therapy Market Size by Regions (2018-2023)
    • 4.2 Americas Bacteriophage Therapy Market Size Growth (2018-2023)
    • 4.3 APAC Bacteriophage Therapy Market Size Growth (2018-2023)
    • 4.4 Europe Bacteriophage Therapy Market Size Growth (2018-2023)
    • 4.5 Middle East & Africa Bacteriophage Therapy Market Size Growth (2018-2023)
  • 5 Americas

    • 5.1 Americas Bacteriophage Therapy Market Size by Country (2018-2023)
    • 5.2 Americas Bacteriophage Therapy Market Size by Type (2018-2023)
    • 5.3 Americas Bacteriophage Therapy Market Size by Application (2018-2023)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Bacteriophage Therapy Market Size by Region (2018-2023)
    • 6.2 APAC Bacteriophage Therapy Market Size by Type (2018-2023)
    • 6.3 APAC Bacteriophage Therapy Market Size by Application (2018-2023)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Bacteriophage Therapy by Country (2018-2023)
    • 7.2 Europe Bacteriophage Therapy Market Size by Type (2018-2023)
    • 7.3 Europe Bacteriophage Therapy Market Size by Application (2018-2023)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Bacteriophage Therapy by Region (2018-2023)
    • 8.2 Middle East & Africa Bacteriophage Therapy Market Size by Type (2018-2023)
    • 8.3 Middle East & Africa Bacteriophage Therapy Market Size by Application (2018-2023)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Bacteriophage Therapy Market Forecast

    • 10.1 Global Bacteriophage Therapy Forecast by Regions (2024-2029)
      • 10.1.1 Global Bacteriophage Therapy Forecast by Regions (2024-2029)
      • 10.1.2 Americas Bacteriophage Therapy Forecast
      • 10.1.3 APAC Bacteriophage Therapy Forecast
      • 10.1.4 Europe Bacteriophage Therapy Forecast
      • 10.1.5 Middle East & Africa Bacteriophage Therapy Forecast
    • 10.2 Americas Bacteriophage Therapy Forecast by Country (2024-2029)
      • 10.2.1 United States Bacteriophage Therapy Market Forecast
      • 10.2.2 Canada Bacteriophage Therapy Market Forecast
      • 10.2.3 Mexico Bacteriophage Therapy Market Forecast
      • 10.2.4 Brazil Bacteriophage Therapy Market Forecast
    • 10.3 APAC Bacteriophage Therapy Forecast by Region (2024-2029)
      • 10.3.1 China Bacteriophage Therapy Market Forecast
      • 10.3.2 Japan Bacteriophage Therapy Market Forecast
      • 10.3.3 Korea Bacteriophage Therapy Market Forecast
      • 10.3.4 Southeast Asia Bacteriophage Therapy Market Forecast
      • 10.3.5 India Bacteriophage Therapy Market Forecast
      • 10.3.6 Australia Bacteriophage Therapy Market Forecast
    • 10.4 Europe Bacteriophage Therapy Forecast by Country (2024-2029)
      • 10.4.1 Germany Bacteriophage Therapy Market Forecast
      • 10.4.2 France Bacteriophage Therapy Market Forecast
      • 10.4.3 UK Bacteriophage Therapy Market Forecast
      • 10.4.4 Italy Bacteriophage Therapy Market Forecast
      • 10.4.5 Russia Bacteriophage Therapy Market Forecast
    • 10.5 Middle East & Africa Bacteriophage Therapy Forecast by Region (2024-2029)
      • 10.5.1 Egypt Bacteriophage Therapy Market Forecast
      • 10.5.2 South Africa Bacteriophage Therapy Market Forecast
      • 10.5.3 Israel Bacteriophage Therapy Market Forecast
      • 10.5.4 Turkey Bacteriophage Therapy Market Forecast
      • 10.5.5 GCC Countries Bacteriophage Therapy Market Forecast
    • 10.6 Global Bacteriophage Therapy Forecast by Type (2024-2029)
    • 10.7 Global Bacteriophage Therapy Forecast by Application (2024-2029)
  • 11 Key Players Analysis

    • 11.1 Armata Pharmaceuticals, Inc.
      • 11.1.1 Armata Pharmaceuticals, Inc. Company Information
      • 11.1.2 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Product Offered
      • 11.1.3 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.1.4 Armata Pharmaceuticals, Inc. Main Business Overview
      • 11.1.5 Armata Pharmaceuticals, Inc. Latest Developments
    • 11.2 Eliava Biopreparations Ltd.
      • 11.2.1 Eliava Biopreparations Ltd. Company Information
      • 11.2.2 Eliava Biopreparations Ltd. Bacteriophage Therapy Product Offered
      • 11.2.3 Eliava Biopreparations Ltd. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.2.4 Eliava Biopreparations Ltd. Main Business Overview
      • 11.2.5 Eliava Biopreparations Ltd. Latest Developments
    • 11.3 Pherecydes Pharma
      • 11.3.1 Pherecydes Pharma Company Information
      • 11.3.2 Pherecydes Pharma Bacteriophage Therapy Product Offered
      • 11.3.3 Pherecydes Pharma Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.3.4 Pherecydes Pharma Main Business Overview
      • 11.3.5 Pherecydes Pharma Latest Developments
    • 11.4 Intralytix, Inc.
      • 11.4.1 Intralytix, Inc. Company Information
      • 11.4.2 Intralytix, Inc. Bacteriophage Therapy Product Offered
      • 11.4.3 Intralytix, Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.4.4 Intralytix, Inc. Main Business Overview
      • 11.4.5 Intralytix, Inc. Latest Developments
    • 11.5 Phagelux Inc.
      • 11.5.1 Phagelux Inc. Company Information
      • 11.5.2 Phagelux Inc. Bacteriophage Therapy Product Offered
      • 11.5.3 Phagelux Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.5.4 Phagelux Inc. Main Business Overview
      • 11.5.5 Phagelux Inc. Latest Developments
    • 11.6 Nextbiotics
      • 11.6.1 Nextbiotics Company Information
      • 11.6.2 Nextbiotics Bacteriophage Therapy Product Offered
      • 11.6.3 Nextbiotics Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.6.4 Nextbiotics Main Business Overview
      • 11.6.5 Nextbiotics Latest Developments
    • 11.7 InnoPhage, Ltd
      • 11.7.1 InnoPhage, Ltd Company Information
      • 11.7.2 InnoPhage, Ltd Bacteriophage Therapy Product Offered
      • 11.7.3 InnoPhage, Ltd Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.7.4 InnoPhage, Ltd Main Business Overview
      • 11.7.5 InnoPhage, Ltd Latest Developments
    • 11.8 Locus Biosciences, Inc.
      • 11.8.1 Locus Biosciences, Inc. Company Information
      • 11.8.2 Locus Biosciences, Inc. Bacteriophage Therapy Product Offered
      • 11.8.3 Locus Biosciences, Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.8.4 Locus Biosciences, Inc. Main Business Overview
      • 11.8.5 Locus Biosciences, Inc. Latest Developments
    • 11.9 TechnoPhage
      • 11.9.1 TechnoPhage Company Information
      • 11.9.2 TechnoPhage Bacteriophage Therapy Product Offered
      • 11.9.3 TechnoPhage Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.9.4 TechnoPhage Main Business Overview
      • 11.9.5 TechnoPhage Latest Developments
    • 11.10 Eligo Bioscience SA
      • 11.10.1 Eligo Bioscience SA Company Information
      • 11.10.2 Eligo Bioscience SA Bacteriophage Therapy Product Offered
      • 11.10.3 Eligo Bioscience SA Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.10.4 Eligo Bioscience SA Main Business Overview
      • 11.10.5 Eligo Bioscience SA Latest Developments
    • 11.11 Phagomed Biopharma GmbH.
      • 11.11.1 Phagomed Biopharma GmbH. Company Information
      • 11.11.2 Phagomed Biopharma GmbH. Bacteriophage Therapy Product Offered
      • 11.11.3 Phagomed Biopharma GmbH. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.11.4 Phagomed Biopharma GmbH. Main Business Overview
      • 11.11.5 Phagomed Biopharma GmbH. Latest Developments
    • 11.12 PhagePro, Inc.
      • 11.12.1 PhagePro, Inc. Company Information
      • 11.12.2 PhagePro, Inc. Bacteriophage Therapy Product Offered
      • 11.12.3 PhagePro, Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.12.4 PhagePro, Inc. Main Business Overview
      • 11.12.5 PhagePro, Inc. Latest Developments
    • 11.13 Adaptive Phage Therapeutics, Inc.
      • 11.13.1 Adaptive Phage Therapeutics, Inc. Company Information
      • 11.13.2 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Product Offered
      • 11.13.3 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.13.4 Adaptive Phage Therapeutics, Inc. Main Business Overview
      • 11.13.5 Adaptive Phage Therapeutics, Inc. Latest Developments
    • 11.14 EnBiotix, Inc.
      • 11.14.1 EnBiotix, Inc. Company Information
      • 11.14.2 EnBiotix, Inc. Bacteriophage Therapy Product Offered
      • 11.14.3 EnBiotix, Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.14.4 EnBiotix, Inc. Main Business Overview
      • 11.14.5 EnBiotix, Inc. Latest Developments
    • 11.15 Intodeworld, Inc.
      • 11.15.1 Intodeworld, Inc. Company Information
      • 11.15.2 Intodeworld, Inc. Bacteriophage Therapy Product Offered
      • 11.15.3 Intodeworld, Inc. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.15.4 Intodeworld, Inc. Main Business Overview
      • 11.15.5 Intodeworld, Inc. Latest Developments
    • 11.16 BiomX Ltd.
      • 11.16.1 BiomX Ltd. Company Information
      • 11.16.2 BiomX Ltd. Bacteriophage Therapy Product Offered
      • 11.16.3 BiomX Ltd. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.16.4 BiomX Ltd. Main Business Overview
      • 11.16.5 BiomX Ltd. Latest Developments
    • 11.17 Phi Therapeutics
      • 11.17.1 Phi Therapeutics Company Information
      • 11.17.2 Phi Therapeutics Bacteriophage Therapy Product Offered
      • 11.17.3 Phi Therapeutics Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.17.4 Phi Therapeutics Main Business Overview
      • 11.17.5 Phi Therapeutics Latest Developments
    • 11.18 Fixed-phage Ltd.
      • 11.18.1 Fixed-phage Ltd. Company Information
      • 11.18.2 Fixed-phage Ltd. Bacteriophage Therapy Product Offered
      • 11.18.3 Fixed-phage Ltd. Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.18.4 Fixed-phage Ltd. Main Business Overview
      • 11.18.5 Fixed-phage Ltd. Latest Developments
    • 11.19 Micreos BV
      • 11.19.1 Micreos BV Company Information
      • 11.19.2 Micreos BV Bacteriophage Therapy Product Offered
      • 11.19.3 Micreos BV Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.19.4 Micreos BV Main Business Overview
      • 11.19.5 Micreos BV Latest Developments
    • 11.20 ContraFect Corporation
      • 11.20.1 ContraFect Corporation Company Information
      • 11.20.2 ContraFect Corporation Bacteriophage Therapy Product Offered
      • 11.20.3 ContraFect Corporation Bacteriophage Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.20.4 ContraFect Corporation Main Business Overview
      • 11.20.5 ContraFect Corporation Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.